Ftse Mib
34.729,20
0,69%
DAX
18.774,71
0,43%
S&P 500
5.304,72
0,70%
NASDAQ
16.920,79
1,10%
Bitcoin
70.453,96
2,84%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ aTyr Pharma Inc (LIFE) aTyr Pharma Inc (LIFE) Notizie

aTyr Pharma Inc

LIFE
1,79
-0,01 (-0,56%)
25 Mag 2024 - Chiuso
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Azione
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
24/5/202422:00GLOBEaTyr Pharma Announces Inducement Grants Under Nasdaq Listing..
24/5/202401:27EDGAR2Form 4 - Statement of changes in beneficial ownership of..
24/5/202401:19EDGAR2Form 4 - Statement of changes in beneficial ownership of..
24/5/202401:11EDGAR2Form 4 - Statement of changes in beneficial ownership of..
24/5/202401:07EDGAR2Form 4 - Statement of changes in beneficial ownership of..
15/5/202413:00GLOBEaTyr Pharma to Present Poster Describing Efzofitimod’s..
14/5/202414:00GLOBEaTyr Pharma Announces Second Positive DSMB Review for..
06/5/202414:00GLOBEaTyr Pharma to Present at Upcoming Investor Conferences
02/5/202422:00GLOBEaTyr Pharma Announces First Quarter 2024 Results and..
01/4/202414:00GLOBEaTyr Pharma to Participate in April Investor Conferences
14/3/202421:00GLOBEaTyr Pharma Announces Fourth Quarter and Full Year 2023..
28/2/202414:00GLOBEaTyr Pharma to Webcast Conference Call Reporting Fourth..
21/2/202414:00GLOBEaTyr Pharma Announces Expanded Access Program (EAP) for..
07/2/202402:20EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07/2/202402:15EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29/1/202414:00GLOBEaTyr Pharma to Present Posters Highlighting Importance of..
18/1/202414:00GLOBEaTyr Pharma Announces Howard University President Emeritus..
10/1/202401:35EDGAR2Form 4 - Statement of changes in beneficial ownership of..
10/1/202401:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/1/202418:21EDGAR2Form SC 13G - Statement of acquisition of beneficial..
13/12/202300:50EDGAR2Form 4 - Statement of changes in beneficial ownership of..
21/11/202306:15EDGAR2Form EFFECT - Notice of Effectiveness
13/11/202322:11EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13/11/202314:00GLOBEaTyr Pharma Presents Poster Demonstrating Preclinical..
09/11/202323:01EDGAR2Form S-3 - Registration statement under Securities Act of..
09/11/202322:42EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
09/11/202322:11EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
09/11/202322:06EDGAR2Form 8-K - Current report
09/11/202322:00GLOBEaTyr Pharma Announces Third Quarter 2023 Results and..
01/11/202313:00GLOBEaTyr Pharma to Present at November Investor Conferences
31/10/202313:00GLOBEaTyr Pharma Announces Dosing of First Patient in Phase 2..
26/9/202315:01EDGAR2Form 8-K - Current report
11/9/202314:04EDGAR2Form 8-K - Current report
11/9/202314:00GLOBEaTyr Pharma Presents Efzofitimod Data Demonstrating..
24/8/202314:00GLOBEaTyr Pharma to Present at the H.C. Wainwright 25th Annual..
10/8/202322:07EDGAR2Form S-8 - Securities to be offered to employees in employee..
09/8/202322:14EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
09/8/202322:10EDGAR2Form 8-K - Current report
09/8/202322:00GLOBEaTyr Pharma Announces Second Quarter 2023 Results and..
01/8/202322:07EDGAR2Form 4 - Statement of changes in beneficial ownership of..
22/6/202314:00GLOBEEuropean Commission Grants Orphan Drug Designation for aTyr..
20/6/202314:00GLOBEaTyr Pharma to Present on Lead Therapeutic Candidate..
09/6/202322:00GLOBEaTyr Pharma Announces Inducement Grants Under Nasdaq Listing..
06/6/202314:00GLOBEaTyr Pharma to Highlight Advancements in tRNA Synthetase..
Apertura: 1,80 Min: 1,7801 Max: 1,8275
Chiusura: 1,80

La tua Cronologia

NASDAQ
LIFE
aTyr Pharma
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network